Table 7.
The interaction between gene promoter region methylation and different cancer stages for 5-year EFS of CRC patients.
| Normal tissues | Tumor tissues | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of subjects | No. of cases (%) | Crude | Adjusted | No. of subjects | No. of cases (%) | Crude | Adjusted | |||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |||||
| ≧2 of genes | ||||||||||||
| UnMe/local (1&2) | 36 | 8 (22.2) | 1.00 | Referent | 1.00 | Referent | 20 | 5 (25.0) | 1.00 | Referent | 1.00 | Referent |
| UnMe/advanced (3&4) | 31 | 19 (61.3) | 3.36 | (1.47 to 7.68) | 5.44 | (1.83 to 16.1) | 8 | 3 (37.5) | 1.32 | (0.32 to 5.53) | 3.52 | (0.58 to 21.3) |
| Me/local (1&2) | 41 | 10 (24.4) | 2.26 | (0.50 to 3.18) | 0.95 | (0.26 to 3.43) | 57 | 13 (22.8) | 0.99 | (0.35 to 2.77) | 1.09 | (0.23 to 5.25) |
| Me/advanced (3&4) | 45 | 38 (84.4) | 5.48 | (2.55 to 11.8) | 8.04 | (2.80 to 23.1) | 68 | 54 (79.4) | 4.48 | (1.79 to 11.2) | 8.01 | (1.92 to 33.4) |
| p for trend | <0.01 | <0.01 | <0.01 | <0.01 | ||||||||
Abbreviations: EFS, event-free survival; CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.
Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade and tumor location.
UnMe/loccal (1&2): DNA promoter region unmethylated with cancer stage 1 or 2.
UnMe/advanced (3&4): DNA promoter region unmethylated with cancer stage 3 or 4.
Me/local (1&2): DNA promoter region methylated with cancer stage 1 or 2.
Me/advanced (3&4): DNA promoter region methylated with cancer stage 3 or 4.